Lysibody
A detailed overview of lysibodies, a novel class of therapeutic antibodies
Lysibodies[edit]

Lysibodies are a novel class of therapeutic antibodies designed to target and neutralize specific bacterial pathogens. Unlike traditional antibodies, lysibodies are engineered to recognize and bind to unique bacterial antigens, facilitating the destruction of the bacteria by the host's immune system.
Structure and Function[edit]
Lysibodies are composed of a monoclonal antibody framework that is modified to include a lysin domain. This domain is responsible for binding to bacterial cell wall components, such as peptidoglycan, which are not present in human cells. This specificity allows lysibodies to selectively target bacteria without affecting human tissues.
The lysin domain of a lysibody is derived from bacteriophage lysins, which are enzymes that degrade bacterial cell walls. By incorporating this domain into the antibody structure, lysibodies can effectively breach the bacterial cell wall, leading to cell lysis and death.
Mechanism of Action[edit]
Upon binding to the bacterial surface, lysibodies recruit components of the host's immune system, such as complement proteins and phagocytes. This recruitment enhances the opsonization and phagocytosis of the bacteria, leading to their clearance from the body.
The dual action of direct bacterial lysis and immune system activation makes lysibodies a powerful tool in combating antibiotic-resistant infections.
Applications[edit]
Lysibodies have shown promise in the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant bacteria. Their ability to target specific bacterial strains while sparing the host's normal flora makes them an attractive option for precision medicine.
Development and Challenges[edit]
The development of lysibodies involves advanced protein engineering techniques to ensure stability, specificity, and efficacy. One of the challenges in lysibody development is the potential for immunogenicity, where the host's immune system may recognize the lysibody as foreign and mount an immune response against it.
Ongoing research is focused on optimizing lysibody design to minimize immunogenicity and enhance their therapeutic potential.
Related pages[edit]
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian